UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Preliminary results from phase II study of combination treatment with
HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in
patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.
Authors*: Robert Hans Ingemar Andtbacka, Merrick I. Ross, Sanjiv S. Agarwala, Matthew H. Taylor,
John T. Vetto, Rogerio Izar Neves, Adil Daud, Hung T. Khong, Richard S. Ungerleider, Aislyn Boran,
Maki Tanaka, Kenneth F. Grossmann
Abstract #: 9543
Presentation Date/Time: Saturday, June 4: 1:00 - 4:30 PM
Location: Hall A, Poster Board #148
Session: Melanoma/Skin Cancers
Citation: J Clin Oncol 34, 2016 (suppl; abstr 9543)
Daud Research Interests: Our group at UCSF is focused on developing new immunotherapy agents and
specifically understanding the biology of the immune response to PD-1 in melanoma. We developed IL-
12 gene therapy in melanoma and carried out the first in human clinical trial in 2005-2007. Based on this
work, IL-12 electroporation is being explored in many cancers as an immune agent and as a combination
treatment with PD-1 and other checkpoint inhibitors in melanoma. I have been involved in the development
of anti-PD-1 antibodies for melanoma. With my colleagues Michael Rosenblum and Max Krummel at
UCSF, we have developed a novel assay that profiles the intra-tumoral microenvironment in depth and can
predict non-response to PD-1. We are currently exploring novel strategies for PD-1 non-responsive subsets
of melanoma (and potentially other cancers).
http://cancer.ucsf.edu/people/profiles/daud_adil.3622
*UCSF authors in bold
32